<mods:mods xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd" version="3.3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mods="http://www.loc.gov/mods/v3"><mods:titleInfo><mods:title>MITOCHONDRIAL MUTATION m.1555A&gt;G IN MT-RNR1 AS A PREDICTIVE BIOMARKER OF AMINOGLYCOSIDE-INDUCED SENSORINEURAL HEARING LOSS IN CHILDREN</mods:title></mods:titleInfo><mods:name type="personal"><mods:namePart type="given">Madrimova</mods:namePart><mods:namePart type="family">A.G</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:abstract>The mitochondrial mutation m.1555A&amp;gt;G in the MT-RNR1 gene (encoding 12S rRNA) structurally remodels the mitochondrial ribosome to resemble its bacterial counterpart, conferring extreme sensitivity to aminoglycoside antibiotics. Even a single standard therapeutic course of gentamicin or amikacin may trigger irreversible bilateral profound deafness in carriers. Given the widespread use of aminoglycosides in neonatal intensive care, identification of at-risk patients prior to drug exposure is of critical clinical importance.
&amp;nbsp;</mods:abstract><mods:originInfo><mods:dateIssued encoding="iso8601">2026-06-10</mods:dateIssued></mods:originInfo><mods:originInfo><mods:publisher>Center for Tech and Media Research</mods:publisher></mods:originInfo><mods:genre>Maqola</mods:genre></mods:mods>